Cogent Biosciences Inc Stock Price, News & Analysis

Cogent Biosciences will present at the 10th Annual SVB Leerlink Global Healthcare Conference on February 25, 2021, from 3:00-3:30 PM ET. CEO Andrew Robbins will lead the presentation. The event can be accessed via the investor relations section of their website, where a live webcast and archived recording will be available. Cogent specializes in developing precision therapies for genetically defined diseases, with its lead program, CGT9486, targeting the KIT D816V mutation related to systemic mastocytosis and gastrointestinal stromal tumors.

Cogent Biosciences (Nasdaq: COGT) announced that CEO Andrew Robbins will present a corporate overview at the LifeSci Partners Precision Oncology Day on February 17, 2021. The event will be held virtually, and a recording of the presentation will be accessible on Cogent's investor relations website after the event. The company focuses on developing precision therapies for genetically defined diseases, with its leading clinical program, CGT9486, addressing the KIT D816V mutation linked to systemic mastocytosis. For updates, follow Cogent on Twitter and LinkedIn.

Cogent Biosciences, Inc. (NASDAQ: COGT) has successfully closed an upsized public offering of 11,794,872 shares at $9.75 per share, raising approximately $108.1 million after costs. This includes the full exercise of the underwriters' option for an additional 1,538,461 shares. The proceeds are earmarked for the ongoing development and regulatory preparation of PLX9486, aimed at treating systemic mastocytosis and gastrointestinal stromal tumors (GIST). The offering was facilitated by Jefferies and Piper Sandler as joint book-running managers.

Cogent Biosciences, Inc. (Nasdaq: COGT) has announced the pricing of an underwritten public offering of 10,256,411 shares at $9.75 per share, up from an initial $60 million to approximately $100 million. The offering includes a 30-day option for underwriters to buy up to 1,538,461 additional shares. Proceeds will support development and regulatory activities for PLX9486 and other candidates, as well as general corporate purposes. The offering is expected to close around December 4, 2020.

Cogent Biosciences, a biotechnology company specializing in precision therapies for genetically defined diseases, has initiated a public offering of $60 million in common stock. Additionally, underwriters have a 30-day option to purchase up to $9 million more. The proceeds will support development and regulatory activities for PLX9486 and other candidates, along with general corporate expenses. Jefferies and Piper Sandler are leading the offering. The registration statement is effective, but these securities are not qualified under state laws.

Cogent Biosciences has appointed Brad Barnett as the new Chief Technology Officer (CTO), effective immediately. Barnett brings nearly 20 years of experience from Array BioPharma, where he played a key role in launching precision oncology medicines. His responsibilities at Cogent will include overseeing chemistry, manufacturing, controls, technical development, and supply chain operations. This leadership change is expected to strengthen Cogent's development plans for its lead product, PLX9486, aimed at treating systemic mastocytosis and gastrointestinal stromal tumors.

Cogent Biosciences (Nasdaq: COGT) will participate in the 3rd Annual Evercore ISI HealthCONx Virtual Conference on December 2, 2020, at 10:55 a.m. ET. CEO Andrew Robbins is scheduled for a virtual fireside chat. Investors can access a live audio webcast via the 'Events' tab on Cogent's investor relations website, with a replay available for 30 days post-event. Cogent focuses on precision therapies for genetically defined diseases, including its advanced clinical program, PLX9486, which targets the KIT D816V mutation.

Cogent Biosciences announced the final results of its Phase 1/2 trial of PLX9486 combined with sunitinib for advanced gastrointestinal stromal tumors (GIST) on Nov 18, 2020. The median progression-free survival (PFS) for treated patients was 12 months, indicating potential effectiveness. With encouraging outcomes documented in patients with imatinib-resistant GIST, Cogent plans to advance this combination into a Phase 3 trial in the second half of 2021. The study included 18 patients, with an overall response rate of 20% and a clinical benefit rate of 80%, showcasing a promising treatment avenue.

Cogent Biosciences, headquartered in Cambridge, MA, announced that CEO Andrew Robbins will present a corporate overview at the Jefferies 2020 Virtual London Healthcare Conference from November 17-19, 2020. The presentation will discuss Cogent’s focus on precision therapies for genetically defined diseases, including their lead program, PLX9486, aimed at inhibiting the KIT D816V mutation associated with systemic mastocytosis and gastrointestinal stromal tumors. A recording of the presentation will be available on their investor relations website.